Drugmaker Rovi’s net profit rises on higher Okedi, heparin sales

Feb 25 (Reuters) – Spanish drugmaker Laboratorios Farmaceuticos Rovi said on Wednesday its 2025 net profit ​rose 3% as higher sales ‌of its schizophrenia drug Okedi and heparin products – as well as recognition of R&D aid – offset a decline in ‌contract ​manufacturing revenue.

(Reporting by Marta Serafinko in Gdansk; Editing by ​David Latona)